Deutsche Bank AG acquired a new position in Biohaven Ltd. (NYSE:BHVN – Free Report) during the 2nd quarter, HoldingsChannel reports. The fund acquired 201,499 shares of the company’s stock, valued at approximately $2,998,000.
A number of other institutional investors have also recently modified their holdings of BHVN. PNC Financial Services Group Inc. grew its holdings in Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after purchasing an additional 1,268 shares during the period. IFP Advisors Inc increased its stake in Biohaven by 55.4% during the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after buying an additional 1,450 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after buying an additional 2,583 shares in the last quarter. Arax Advisory Partners raised its stake in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after purchasing an additional 4,443 shares during the last quarter. Finally, Essential Partners LLC lifted its stake in shares of Biohaven by 31.7% in the first quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock worth $76,000 after buying an additional 2,169 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.
Key Biohaven News
Here are the key news stories impacting Biohaven this week:
- Positive Sentiment: Major epilepsy licensing agreement: Biohaven licensed its Kv7 ion-channel platform, including lead epilepsy candidate opakalim, to SK Biopharmaceuticals in a deal potentially worth up to $795 million. The agreement includes upfront and milestone payments, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
- Positive Sentiment: Validation and potential funding: Opakalim is in Phase 2/3 development for focal epilepsy, and the partnership gives Biohaven a potential source of non-dilutive capital while adding a global development and commercialization partner. The deal also increased investor focus on the company’s broader pipeline. Biohaven and SK Biopharmaceuticals licensing announcement
- Positive Sentiment: Favorable trade-secret ruling: A federal court confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, formalizing a $4 million award to Biohaven and Yale University. The ruling removes uncertainty around the case and provides a financial recovery for Biohaven. Biohaven trade-secret lawsuit ruling
- Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026. The licensing deal improves the commercial outlook, but milestone payments and royalties remain dependent on development, regulatory and sales outcomes. BHVN stock and upcoming trial readout
Biohaven Stock Up 19.1%
Biohaven (NYSE:BHVN – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). As a group, equities analysts expect that Biohaven Ltd. will post -3.29 earnings per share for the current fiscal year.
Analyst Ratings Changes
BHVN has been the topic of a number of recent research reports. TD Cowen reissued a “buy” rating on shares of Biohaven in a research note on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Needham & Company LLC set a $11.00 target price on Biohaven in a research report on Monday, June 29th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $30.00 target price on shares of Biohaven in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Biohaven currently has an average rating of “Moderate Buy” and a consensus price target of $18.94.
Read Our Latest Analysis on BHVN
Biohaven Company Profile
Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.
The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.
Featured Stories
- Five stocks we like better than Biohaven
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd. (NYSE:BHVN – Free Report).
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
